ERBB3 and breast carcinoma: Lyu et al24 showed that in breast cancer, miR‐542‐3p bound specifically to three binding sites on the 3′UTR of Survivin mRNA to inhibit Survivin expression, enhance the pro‐apoptosis effect of paclitaxel in HER2‐overexpressing breast cancer cells, and inhibit HER3‐mediated drug resistance to paclitaxel.